Climb Bio FY2026 Earnings Forecast Boosted by HC Wainwright

Climb Bio logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2026 EPS forecast for Climb Bio to a loss of $0.74 per share from a projected loss of $0.76, while maintaining a Buy rating.
  • Climb Bio reported a quarterly loss of $0.18 per share, beating analyst consensus for a loss of $0.20 by $0.02.
  • Analyst sentiment is broadly positive: the stock has an average Buy rating and an average price target of $28.14, according to MarketBeat.
  • Interested in Climb Bio? Here are five stocks we like better.

Climb Bio, Inc. (NASDAQ:CLYM - Free Report) - Research analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of Climb Bio in a report released on Monday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.74) per share for the year, up from their previous forecast of ($0.76). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Climb Bio's current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Climb Bio's Q4 2026 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.25) EPS, Q4 2027 earnings at ($0.26) EPS and FY2027 earnings at ($0.97) EPS.

Climb Bio (NASDAQ:CLYM - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.02.

CLYM has been the subject of a number of other reports. BTIG Research reaffirmed a "buy" rating and issued a $32.00 target price on shares of Climb Bio in a research note on Tuesday, October 27th. Wall Street Zen raised shares of Climb Bio from a "sell" rating to a "hold" rating in a research report on Saturday. Robert W. Baird boosted their price target on shares of Climb Bio from $21.00 to $25.00 and gave the company an "outperform" rating in a research report on Thursday, September 3rd. Guggenheim reissued a "buy" rating on shares of Climb Bio in a report on Monday, October 26th. Finally, Piper Sandler reissued an "overweight" rating on shares of Climb Bio in a report on Tuesday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $28.14.

Read Our Latest Research Report on CLYM

Climb Bio Stock Performance

NASDAQ CLYM opened at $11.74 on Wednesday. The stock's fifty day moving average is $11.80 and its two-hundred day moving average is $10.53. The firm has a market capitalization of $689.61 million, a P/E ratio of -14.32 and a beta of 0.01. Climb Bio has a fifty-two week low of $1.63 and a fifty-two week high of $18.33.

Insider Activity at Climb Bio

In other news, Director Stephen Thomas sold 100,000 shares of Climb Bio stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $13.67, for a total transaction of $1,367,000.00. Following the sale, the director owned 467,969 shares of the company's stock, valued at approximately $6,397,136.23. The trade was a 17.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.60% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. State of Wyoming purchased a new stake in Climb Bio in the third quarter valued at $31,000. Legal & General Group Plc acquired a new position in shares of Climb Bio in the 2nd quarter valued at $45,000. Spark Investment Management LLC acquired a new position in shares of Climb Bio in the 2nd quarter valued at $177,000. Profund Advisors LLC acquired a new position in shares of Climb Bio in the 3rd quarter valued at $190,000. Finally, Bank of America Corp DE purchased a new position in shares of Climb Bio during the 2nd quarter worth $335,000. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

About Climb Bio

(Get Free Report)

Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production. Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy. Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity.

Featured Articles

Earnings History and Estimates for Climb Bio (NASDAQ:CLYM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Climb Bio Right Now?

Before you consider Climb Bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.

While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines